Karo Pharma (KARO.ST) Stock Price
Karo Pharma Price
Over the last 19 years Karo Pharma grew revenue by 16.0% annually, reaching 2.96 B SEK. Earnings per share have declined at 25.6% per year over the last 4 years. For Karo Pharma, the net margin of -0.6% is down versus 2.2% a few years ago. At today's price the dividend yield works out to roughly 0.49%. The payout ratio is around 7% of earnings.
Karo Pharma stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Karo Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Karo Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Karo Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Karo Pharma Price |
|---|
Karo Pharma Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Karo Pharma Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB SEK |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB SEK |
| EBITM SEK |
| EBIT MARGIN% |
| NET INCOMEM SEK |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | 0.03 | 0.05 | 0.03 | 0.07 | 0.35 | 0.66 | 1.62 | 1.90 | 2.88 | 2.96 | 4.24 | 4.54 | 4.82 | 4.86 | 4.91 |
| – | – | 42.42 | -36.17 | 130.00 | 402.90 | 89.34 | 145.81 | 17.71 | 51.60 | 2.74 | 43.16 | 7.20 | 6.10 | 0.77 | 1.13 |
| – | 5,169.70 | 100.00 | 100.00 | 40.58 | 42.65 | 51.90 | 71.58 | 68.54 | 55.34 | 57.62 | 57.62 | 57.62 | 57.62 | 57.62 | 57.62 |
| 1.71 | 1.71 | 0.05 | 0.03 | 0.03 | 0.15 | 0.34 | 1.16 | 1.30 | 1.60 | 1.71 | 2.44 | 2.62 | 2.78 | 2.80 | 2.83 |
| – | – | -25.00 | -59.00 | -60.00 | 29.00 | 79.00 | 414.00 | 172.00 | 250.00 | 205.00 | 209.00 | 363.00 | 426.00 | 560.00 | 656.00 |
| – | – | -53.19 | -196.67 | -86.96 | 8.36 | 12.02 | 25.63 | 9.05 | 8.67 | 6.92 | 4.93 | 7.99 | 8.84 | 11.53 | 13.35 |
| – | – | -22.00 | -59.00 | -77.00 | 95.00 | 14.00 | 657.00 | 8.00 | 82.00 | -17.00 | – | – | 66.00 | 163.00 | 409.00 |
| – | – | – | 168.18 | 30.51 | -223.38 | -85.26 | 4,592.86 | -98.78 | 925.00 | -120.73 | – | – | – | 146.97 | 150.92 |
| 224.35 | 224.35 | 224.35 | 224.35 | 224.35 | 79.45 | 90.76 | 168.41 | 222.57 | 223.09 | 224.35 | 224.35 | 224.35 | 224.35 | 224.35 | 224.35 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Karo Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Karo Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Karo Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Karo Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Karo Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Karo Pharma stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Karo Pharma Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Karo Pharma business model & stock analysis
Karo Pharma SWOT Analysis
Strengths
Karo Pharma AB has a strong market presence and brand recognition in the pharmaceutical industry.
The company has an extensive portfolio of high-quality products, offering a wide range of options to its customers.
Karo Pharma AB enjoys strong relationships with healthcare professionals and key stakeholders in the industry.
Weaknesses
The company is highly dependent on a limited number of products for its revenue, which poses a risk to its financial stability.
Karo Pharma AB has limited diversification in terms of geographical presence, primarily focusing on specific regions.
The company may face challenges in adapting to rapid technological advancements in the pharmaceutical field.
Opportunities
There is a growing demand for innovative pharmaceutical products, which presents an opportunity for Karo Pharma AB to expand its product offerings.
Expansion into new geographical markets can provide Karo Pharma AB with access to new customer segments and revenue streams.
Increasing advancements in research and development offer opportunities for Karo Pharma AB to develop new, more effective drugs.
Threats
The pharmaceutical industry is highly regulated, and changes in regulations may impact Karo Pharma AB's operations and profitability.
Competition within the pharmaceutical industry is intense, and Karo Pharma AB faces the risk of losing market share to larger, more established competitors.
Economic downturns and fluctuations in currency exchange rates can affect the company's financial performance and export capabilities.
Karo Pharma Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Karo Pharma historical P/E ratio, EBIT multiple, and P/S ratio
Karo Pharma annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Karo Pharma shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Karo Pharma Dividend History
2 years of dividend payments
Karo Pharma dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Karo Pharma Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 2/23/2023 | 0.06SEK | - | 1.21 BSEK | - | 2022 Q4 |
| 10/25/2022 | 0.01SEK | - | 1.06 BSEK | - | 2022 Q3 |
| 7/20/2022 | 0.02SEK | - | -SEK | - | 2022 Q2 |
| 5/2/2022 | -0.02SEK | - | -SEK | - | 2022 Q1 |
| 2/25/2022 | 0.23SEK | - | 803.88 MSEK | - | 2021 Q4 |
| 10/28/2021 | 0.05SEK | - | 751.10 MSEK | - | 2021 Q3 |
| 7/22/2021 | 0.28SEK | - | 803.88 MSEK | - | 2021 Q2 |
| 4/21/2021 | 0.56SEK | - | 724.71 MSEK | - | 2021 Q1 |
| 2/18/2021 | 0.49SEK | - | 738.92 MSEK | - | 2020 Q4 |
| 10/30/2020 | 0.45SEK | - | 701.36 MSEK | - | 2020 Q3 |
Karo Pharma shareholder structure
| % | Name |
|---|---|
105.67084% | |
0.91327% | |
0.39428% | |
0.39193% | |
0.22059% | |
0.21047% |
Karo Pharma Executives and Management Board
17 members · avg. age 49 · 41 % women
Mr. Christoffer Lorenzen (45)
Chief Executive Officer · since 2019
11.89 M SEK
Management
Mr. Jon Johnsson (45)
Chief Financial Officer
Ms. Anna Hale
Chief Marketing Officer
Mr. Jonathan Kimber (50)
Vice President - Operations
Ms. Anna Elmblad (44)
Vice President - Strategic Marketing
Ms. Sofia Pedersen (38)
Vice President - Scientific Affairs
Ms. Lisa Westerdahl (46)
Vice President - Commercial Pharma Operations & Corporate Communications · since 2020
Board of Directors
Dr. Bo Hansen (62)
Independent Chairman of the Board
Ms. Erika Henriksson (39)
Director
Mr. Vesa Koskinen (42)
Director
Mr. Hakan Astroem (73)
Independent Director · since 2017
Dr. Flemming Ornskov (63)
Independent Director
Ms. Uta Kemmerich-Keil (55)
Independent Director
Karo Pharma Supply Chain
Karo Pharma Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.42 | -0.37 | 0.07 |
Frequently asked questions about Karo Pharma
The business model of Karo Pharma AB focuses on the development, production, and marketing of pharmaceutical products. As a leading specialty pharmaceutical company in Sweden, Karo Pharma AB aims to improve the health and wellbeing of individuals through its diverse portfolio of prescription and over-the-counter medications. The company leverages its strong research and development capabilities to bring innovative and high-quality drugs to market. With a customer-centric approach, Karo Pharma AB strives to address various therapeutic areas and provide effective solutions for patients, healthcare professionals, and partners worldwide.
Karo Pharma AB is primarily active in the pharmaceutical industry.
Karo Pharma AB faces strong competition from various companies in the market. Some of its main competitors include Orifarm Group, Meda AB, and Mylan NV. These companies operate in the same pharmaceutical industry and offer similar products, making the market highly competitive. Karo Pharma AB strives to differentiate itself by focusing on providing innovative and high-quality pharmaceutical solutions. By consistently delivering effective medications and maintaining strong relationships with healthcare professionals and consumers, Karo Pharma AB aims to stay ahead of its rivals in the market.
Karo Pharma AB, a leading pharmaceutical company, has an impressive history and background. Established in 1987, the company has since grown to become a prominent player in the healthcare industry. Karo Pharma specializes in the development, production, and marketing of effective and high-quality medical products. With a strong focus on innovation and research, the company has built a robust portfolio of prescription and over-the-counter medications. Karo Pharma's commitment to excellence and customer satisfaction has propelled its success in both domestic and international markets. With a rich history of over three decades, Karo Pharma AB continues to make significant contributions to the pharmaceutical sector through its cutting-edge products and unwavering dedication to improving global healthcare.
Karo Pharma AB has achieved several significant milestones. The company successfully acquired Weifa ASA, a leading Norwegian pharmaceutical company, thereby expanding its product portfolio and market presence. Karo Pharma AB also secured a strong financial position by successfully completing a fully underwritten rights issue. This allowed the company to strengthen its strategic focus on development, marketing, and sales of prescription and consumer healthcare products. Additionally, Karo Pharma AB successfully launched new products in key therapeutic areas, further establishing itself as a prominent player in the pharmaceutical industry. These milestones demonstrate the company's commitment to growth, innovation, and providing high-quality healthcare solutions.
Karo Pharma AB is primarily present in the Scandinavian region, including Sweden, Norway, Denmark, and Finland.
Karo Pharma AB represents values of innovation, integrity, and excellence in the pharmaceutical industry. With a strong corporate philosophy focused on delivering high-quality healthcare solutions, Karo Pharma AB aims to improve patient well-being and enhance their quality of life. The company prioritizes research and development to discover and develop innovative treatments for various medical conditions. Karo Pharma AB is committed to upholding ethical standards, fostering collaborative relationships, and maintaining a sustainable approach in all their endeavors. Through their dedication to excellence, Karo Pharma AB continues to make significant contributions to the healthcare industry.
9 analysts currently rate the Karo Pharma stock: 0 recommend buying, 3 holding and 6 selling.
Converted at the current exchange rate, the Karo Pharma share trades at 5.54 EUR (60.70 SEK).
The Karo Pharma share (KARO.ST) is listed on 5 stock exchanges, including: Frankfurt (KA6N.F), München (KA6N.MU), London (0RAQ.L).
Karo Pharma AB is a Swedish pharmaceutical company specializing in the development, manufacturing, and marketing of high-quality branded and OTC products. The company is divided into two main business areas, namely the Consumer Healthcare and Prescription Products divisions. The Consumer Healthcare division includes a wide range of OTC products available in supermarkets, drugstores, and pharmacies. Brands include products such as Tavegyl, Aqualia, Alvedon, Idomin, and Nalox, to name a few. These products cover a variety of indications, including pain and inflammation, allergies, skincare, sleep disorders, and digestive complaints. Karo Pharma's Prescription Products division is dedicated to the development and marketing of prescription drugs and medical devices in Scandinavia. The company works closely with healthcare professionals to meet the needs of patients in various therapeutic areas. Products include medications such as Riftan, Trianal, Ketogan, and Acetylcysteine, as well as medical devices such as inhalable respiratory medications and pain medications. Karo Pharma's business model is based on an "asset-light" approach, where the company acquires high-quality products and brands from third parties to sell them on local and international markets. This allows the company to focus on product development and marketing without the costly manufacturing expenses and building of production facilities. Another key component of Karo Pharma's business model is the continuous investment in research and development. The company has a strong pipeline of new products and technologies that it wants to bring to the market to increase its market presence and growth. Additionally, the company has a strong focus on utilizing innovative technologies to optimize its business processes and increase efficiency and profitability. In conclusion, Karo Pharma's business model is based on the development and marketing of innovative and high-quality drugs and medical devices, as well as branded OTC products, using an asset-light approach. The company aims to continuously grow and strengthen its market presence in national and international markets through research, development, and efficiency optimization.
The revenue cannot currently be calculated for Karo Pharma.
The profit cannot currently be calculated for Karo Pharma.
The P/E ratio cannot be calculated for Karo Pharma at the moment.
The P/S cannot be calculated for Karo Pharma currently.
The Eulerpool Quality Score for Karo Pharma is 1/10.
The ISIN of Karo Pharma is SE0007464888. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Karo Pharma is A14YW4. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Karo Pharma is KARO.ST. The ticker symbol is used to trade Karo Pharma shares on the stock exchange.
The current dividend yield of Karo Pharma is 0.49 %.
Karo Pharma paid dividends every year for the past 0 years.
Karo Pharma is assigned to the 'Health' sector.
To receive the latest dividend of Karo Pharma from amounting to 0.3 SEK, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
The dividends of Karo Pharma are distributed in SEK.
Karo Pharma stock
Karo Pharma Peer Group
Karo Pharma Ticker
Karo Pharma FIGI
All fundamentals and in-depth analysis of Karo Pharma
Our stock analysis for Karo Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karo Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.